Tom 7, Nr 4 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2023-03-08
Wyświetlenia strony 439
Wyświetlenia/pobrania artykułu 104
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Stanowisko Ekspertów Polskiego Towarzystwa Ginekologów i Położników dotyczące stosowania relugoliksu w terapii skojarzonej — 40 mg relugoliksu, 1 mg estradiolu i 0,5 mg octanu noretysteronu (preparat Ryeqo®) w leczeniu objawowych mięśniaków macicy u kobiet

Tomasz Rechberger1, Artur Jakimiuk2, Rafał Stojko3, Maria Szubert4, Piotr Sieroszewski5
Ginekologia i Perinatologia Praktyczna 2022;7(4):217-225.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Bulun SE, Bulun SE. Uterine fibroids. N Engl J Med. 2013; 369(14): 1344–1355.
  2. Donnez J, Courtoy GE, Dolmans MM, et al. Fibroid management in premenopausal women. Climacteric. 2019; 22(1): 27–33.
  3. Ciarmela P, Islam MdS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011; 17(6): 772–790.
  4. Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124(10): 1501–1512.
  5. Walker CL, Cesen-Cummings K, Houle C, et al. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis. 2001; 22(12): 2049–2052.
  6. Dolmans MM, Donnez J, Fellah L, et al. Uterine fibroid management: Today and tomorrow. J Obstet Gynaecol Res. 2019; 45(7): 1222–1229.
  7. Islam MdS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013; 100(1): 178–193.
  8. Ciebiera M, Włodarczyk M, Słabuszewska-Jóźwiak A, et al. Influence of vitamin D and transforming growth factor β3 serum concentrations, obesity, and family history on the risk for uterine fibroids. Fertil Steril. 2016; 106(7): 1787–1792.
  9. Al-Hendy A, Myers ER, Stewart E, et al. Uterine Fibroids: Burden and Unmet Medical Need. Semin Reprod Med. 2017; 35(6): 473–480.
  10. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003; 188(1): 100–107.
  11. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016; 22(6): 665–686.
  12. Wallach E, Buttram V, Reiter R, et al. Uterine leiomyomata: etiology, symptomatology, and management. Fertility and Sterility. 1981; 36(4): 433–445.
  13. Lasmar RB, Lasmar BP, Lasmar RB, et al. The role of leiomyomas in the genesis of abnormal uterine bleeding (AUB). Best Pract Res Clin Obstet Gynaecol. 2017; 40: 82–88.
  14. Downes E, Sikirica V, Gilabert-Estelles J, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010; 152(1): 96–102.
  15. Ghosh S, Naftalin J, Imrie R, et al. Natural History of Uterine Fibroids: A Radiological Perspective. Curr Obstet Gynecol Rep. 2018; 7(3): 117–121.
  16. Vilos GA, Allaire C, Laberge PY, et al. SPECIAL CONTRIBUTORS. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015; 37(2): 157–178.
  17. Borah BJ, Nicholson WK, Bradley L, et al. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013; 209(4): 319.e1–319.e20.
  18. Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol. 2001; 44(2): 385–400.
  19. Kotani Y, Tobiume T, Fujishima R, et al. Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy. J Obstet Gynaecol Res. 2018; 44(2): 298–302.
  20. Spies JB. Current Role of Uterine Artery Embolization in the Management of Uterine Fibroids. Clin Obstet Gynecol. 2016; 59(1): 93–102.
  21. Łoziński T, Filipowska J, Gurynowicz G, et al. The effect of high-intensity focused ultrasound guided by magnetic resonance therapy on obstetrical outcomes in patients with uterine fibroids - experiences from the main Polish center and a review of current data. Int J Hyperthermia. 2019; 36(1): 582–590.
  22. Zupi E, Centini G, Sabbioni L, et al. Nonsurgical Alternatives for Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol. 2016; 34: 122–131.
  23. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril. 1990; 54(3): 419–427.
  24. Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017; 11: CD000547.
  25. Osuga Y, Enya K, Kudou K, et al. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2019; 133(3): 423–433.
  26. Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Pract Res Clin Obstet Gynaecol. 2007; 21(1): 57–65.
  27. Brown J, Pan A, Hart R. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews. 2010.
  28. Donnez J, Pirard C, Smets M, et al. Surgical management of endometriosis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2004; 18(2): 329–348.
  29. Donnez J, Nisolle M, Clerckx F, et al. Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis, and the role of gonadotrophin-releasing hormone agonist treatment. Br J Obstet Gynaecol. 1994; 101 Suppl 10: 2–9.
  30. Ng J, Chwalisz K, Carter DC, et al. Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women. J Clin Endocrinol Metab. 2017; 102(5): 1683–1691.
  31. Myovant Sciences. Relugolix Japanese prescribing information; 2019. http://www.pmda.go. jp/PmdaS earch /iyaku Detai l/Resul tData SetPD F/40025 6_24990 13F10 27_1_02 Accessed. ; 7: March.
  32. Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014; 723: 167–174.
  33. Lukes A. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol/norethindrone acetate add-back therapy. .
  34. Hoshiai H, Seki Y, Kusumoto T, et al. Phase 2 Study of Relugolix vs Placebo in Heavy Menstrual Bleeding Associated With Uterine Fibroids [17H]. Obstetrics & Gynecology. 2017; 129(1).
  35. Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019; 112(5): 922–929.e2.
  36. Al-Hendy A, Lukes AS, Poindexter AN, et al. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021; 384(7): 630–642.
  37. Hallberg L, Högdahl AM, Nilsson L, et al. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966; 45(3): 320–351.
  38. Munro MG, Critchley HOD, Fraser IS, et al. FIGO Menstrual Disorders Committee, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018; 143(3): 393–408.
  39. Giudice L, As-Sanie S, Ferreira JA, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). The Lancet. 2022; 399(10343): 2267–2279.
  40. Gaetke-Udager K, McLean K, Sciallis AP, et al. Diagnostic Accuracy of Ultrasound, Contrast-enhanced CT, and Conventional MRI for Differentiating Leiomyoma From Leiomyosarcoma. Acad Radiol. 2016; 23(10): 1290–1297.
  41. Exacoustos C, Romanini ME, Amadio A, et al. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound. 2007; 35(8): 449–457.
  42. Ludovisi M, Moro F, Pasciuto T, et al. Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma. Ultrasound Obstet Gynecol. 2019; 54(5): 676–687.
  43. Sun S, Bonaffini PA, Nougaret S, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019; 100(10): 619–634.
  44. Kim JA, Lee MS, Choi JS. Sonographic findings of uterine endometrial stromal sarcoma. Korean J Radiol. 2006; 7(4): 281–286.
  45. Woźniak A, Woźniak S. Ultrasonography of uterine leiomyomas. Prz Menopauzalny. 2017; 16(4): 113–117.
  46. Aviram R, Ochshorn Y, Markovitch O, et al. et al.. J Clin Ultrasound. 2005; 33: 10–3.
  47. Szabó I, Szánthó A, Csabay L, et al. Color Doppler ultrasonography in the differentiation of uterine sarcomas from uterine leiomyomas. Eur J Gynaecol Oncol. 2002; 23(1): 29–34.
  48. Shah SH, Jagannathan JP, Krajewski K, et al. Uterine sarcomas: then and now. AJR Am J Roentgenol. 2012; 199(1): 213–223.



Ginekologia i Perinatologia Praktyczna